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The kinase eEF2K [eukaryotic elongation factor 2 (eEF2) kinase] controls the rate of peptide chain elon-
gation by phosphorylating eEF2, the protein that mediates the movement of the ribosome along the
mRNA by promoting translocation of the transfer RNA from the A to the P site in the ribosome.
eEF2K-mediated phosphorylation of eEF2 on threonine 56 (Thr56) decreases its affinity for the ribosome,
thereby inhibiting elongation. Here, we show that in response to genotoxic stress, eEF2K was activated
by AMPK (adenosine monophosphate–activated protein kinase)–mediated phosphorylation on serine
398. Activated eEF2K phosphorylated eEF2 and induced a temporary ribosomal slowdown at the stage
of elongation. Subsequently, during DNA damage checkpoint silencing, a process required to allow cell
cycle reentry, eEF2K was degraded by the ubiquitin-proteasome system through the ubiquitin ligase
SCFbTrCP (Skp1–Cul1–F-box protein, b-transducin repeat–containing protein) to enable rapid resumption
of translation elongation. This event required autophosphorylation of eEF2K on a canonical bTrCP-
binding domain. The inability to degrade eEF2K during checkpoint silencing caused sustained phos-
phorylation of eEF2 on Thr56 and delayed the resumption of translation elongation. Our study therefore
establishes a link between DNA damage signaling and translation elongation.
INTRODUCTION
Cells activate surveillance molecular networks known as DNA damage
checkpoints to protect their genome from environmental and metabolic
genotoxic stress. Depending on the type and extent of DNA lesions
and the cellular context, damaged cells with an activated checkpoint
can undergo senescence, die by apoptotic cell death, or repair the dam-
aged genome and, after checkpoint termination, resume their physiolog-
ical functions (1, 2).
Genotoxic stress has a greater effect on gene expression at the level of
mRNA translation than at the level of transcription (3). This may be due
to the fact that protein synthesis requires about 40% of the total cellular
energy, and cells need to couple stress responses to metabolic demands
(4). Indeed, it is conceivable that in response to genotoxic stress, cells aim
to preserve energy by reducing protein synthesis to be able to repair the
damage.
The mTOR (mammalian target of rapamycin) pathway integrates
growth and stress signals and promotes protein synthesis. mTOR regu-
lates several critical components involved in both translation initiation
and elongation. mTOR-mediated phosphorylation of two proteins that
promote translation initiation, the p70 ribosomal S6 kinase (S6K) and
eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), in-
creases their activity (5, 6). In addition, mTOR promotes translation elon-
gation by inhibiting eukaryotic elongation factor 2 (eEF2) kinase
(eEF2K), which phosphorylates and inactivates eEF2, a factor that med-
iates the translocation step of peptide-chain elongation (7–13). eEF2K-
mediated phosphorylation of eEF2 on Thr56 reduces the affinity of
eEF2 for the ribosome, thereby inhibiting its function (13–23). The ac-
tivity of eEF2K is controlled under various conditions. For example,
stimuli that induce protein synthesis trigger the inactivation of eEF2K
and the subsequent dephosphorylation of eEF2 (24). In contrast, deficien-
cies in nutrients or energy lead to activation of eEF2K and impairment of
translation elongation.
Despite the major impact of genotoxic stress on mRNA translation,
no information is available on how translation elongation is affected by
genotoxic stress, and, more generally, there have been few studies directed
to understanding the regulation of protein synthesis by the DNA damage
response. DNA damage inhibits the mTOR-S6K axis through p53, a key
sensor of genotoxic stress, thereby leading to decreased protein synthesis
(25, 26). Moreover, the activity of TSC2 (tuberous sclerosis 2), a crucial
inhibitor of mTOR, has been reported to be induced by p53 (26).
Numerous studies haveuncovered fundamental functions of the ubiquitin-
proteasome system in the DNA damage response (1, 2, 27). This system
involves two discrete and sequential processes: the tagging of substrates
by covalent attachment of multiple ubiquitin molecules and the degrada-
tion of polyubiquitylated proteins by the 26S proteasome (28). Ubiquitin
is transferred and covalently attached to substrates through an enzymatic
cascade involving ubiquitin-activating enzymes (E1), ubiquitin-conjugating
enzymes (E2), and ubiquitin ligases (E3). E3 ubiquitin ligases repre-
sent the essential regulators of ubiquitylation because they physically
interact with target substrates, linking them to E2 ubiquitin-conjugating
enzymes.
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SCFbTrCP (Skp1–Cul1–F-box protein, b-transducin repeat–containing
protein) is a multisubunit RING finger–type ubiquitin ligase composed
of a cullin scaffold, Cul1, which simultaneously interacts with the RING
subunit Rbx1 and the adaptor protein Skp1 (29–32). Skp1 in turn binds
the F-box protein bTrCP, the substrate receptor subunit that recruits spe-
cific substrate proteins. Through its WD40 b-propeller structure, bTrCP
recognizes a diphosphorylatedmotif with the consensus DpSGXX(X)pS
in which the serine residues are phosphorylated to allow interaction
with bTrCP.
Here, we show that upon genotoxic stress, eEF2K is first activated by
AMPK (adenosine monophosphate–activated protein kinase)–mediated
phosphorylation to induce a temporary translational slowdown at the
stage of elongation and then, during checkpoint silencing, is targeted
for proteasome-dependent degradation by the ubiquitin ligase SCFbTrCP to
allow rapid and efficient resumption of translation. These findings estab-
lish an important link between DNA damage response and translation
of mRNAs.
RESULTS
eEF2K specifically interacts with bTrCP1 and bTrCP2
To identify substrates of the ubiquitin ligase SCFbTrCP, we used immuno-
affinity chromatography followed by tandem mass spectrometry (MS/MS).
We expressed FLAG–hemagglutinin (HA) epitope–tagged bTrCP2
(FLAG-HA-bTrCP2) in human embryonic kidney (HEK) 293T cells
and analyzed by MS proteins that co-purified with FLAG-HA-bTrCP2
after sequential FLAG and HA immunoprecipitations. We unambiguously
identified eEF2K, recording 26 spectra corresponding to nine unique pep-
tides (fig. S1A). To validate the interaction between bTrCP and eEF2K,
we examined the ability of FLAG-tagged versions of 29 F-box proteins
expressed in HEK293T cells to bind to endogenous eEF2K. bTrCP1 and
bTrCP2 were the only F-box proteins that interacted with eEF2K (Fig. 1A
and fig. S1B). bTrCP1 and bTrCP2 share identical biochemical properties
and substrates; hence, the term bTrCP will refer to both unless specified
otherwise. The bTrCP-eEF2K interaction was detected in other cell types
and thus was not restricted to HEK293T cells (fig. S1C). Moreover, when
we followed the reciprocal approach and immunopurified eEF2K expressed
in HEK293T cells, we recovered peptides corresponding to bTrCP1 (one
unique peptide), bTrCP2 (four unique peptides), and the SCF adaptor
Skp1 (one unique peptide) (fig. S1, D to F). The ability of eEF2K to im-
munoprecipitate the bTrCP1-Skp1 complex was confirmed by immuno-
precipitation followed by immunoblotting (Fig. 1B). The interaction of
endogenous bTrCP1 and eEF2K was also observed (Fig. 1C).
To obtain insight into the nature of the bTrCP-eEF2K interaction, we
mutated the arginine residue (Arg474 of human bTrCP1, isoform 2) in the
WD40 b-propeller structure of bTrCP1 that interacts with the substrate
destruction motif (32) and analyzed its ability to bind eEF2K. Whereas
wild-type bTrCP1 immunoprecipitated eEF2K and the established
bTrCP1 substrate PDCD4, the bTrCP1(R474A) mutant did not (Fig.
1D, left panels). Similar results were obtained when we mutated the
equivalent arginine residue in bTrCP2 (Arg447 of human bTrCP2, isoform
C; Fig. 1D, right panels).
eEF2K interaction with bTrCP requires a conserved
phosphodegron
The WD40 b-propeller structure of bTrCP binds its substrates through a
diphosphorylated degradation motif (phosphodegron) with the consensus
DpSGXX(X)pS (30–32), but some substrates of bTrCP have one or both
serine residues replaced by either aspartic acid or glutamic acid (33–35).
eEF2K has four of these potential bTrCP-binding domains (Fig. 2A, top).
To identify the domain required for the interaction with bTrCP, we gener-
ated various serine–, aspartic acid–, or glutamic acid–to–alanine double
mutants and examined their ability to bind bTrCP. The eEF2K(S441A/
S445A) mutant immunoprecipitated less bTrCP1 compared to wild-type
eEF2K, eEF2K(S71A/S78A), eEF2K(S72A/S78A), eEF2K(S622A/
S627A), or eEF2K(E652A/D657A) (Fig. 2A, bottom). The motif
surrounding Ser441 and Ser445 is highly conserved in vertebrate orthologs
of eEF2K (Fig. 2B).
Next, we used MS to analyze phosphorylation of eEF2K in this re-
gion (36). FLAG epitope–tagged eEF2K was coexpressed with a Cul1
dominant-negative deletion mutant [Cul1-N252 (37)] in HEK293T cells
and immunopurified. Analysis of the recovered eEF2K phosphopeptides
demonstrated that Ser441 and Ser445 were phosphorylated in cells (fig. S2).
To test whether phosphorylation is required for the interaction of eEF2K
with bTrCP, we used immobilized synthetic peptides that make up the
bTrCP-binding domain of eEF2K (amino acids 438 to 450 in human
eEF2K). Although an eEF2K peptide containing phosphorylated Ser441
and Ser445 interacted with bTrCP1 (but not with FBXW5), the corre-
sponding nonphosphorylated peptidewas unable to do so (Fig. 2C), indi-
cating that phosphorylation of Ser441 and Ser445 was required for the
association with bTrCP.
To test whether SCFbTrCP was directly responsible for the polyubiquityl-
ation of eEF2K, we reconstituted the ubiquitylation of eEF2K in vitro.
Immunopurified bTrCP1, but not an inactive bTrCP1(DF-box) mutant, in-
duced the in vitro ubiquitylation of eEF2K (Fig. 2D). Moreover, the
eEF2K(S441A/S445A) mutant was not efficiently ubiquitylated by bTrCP
in vitro (fig. S3). Thus, consistently with our findings in cultured cells, the
in vitro data show that bTrCP promotes the ubiquitylation of eEF2K in a
phosphodegron-dependent manner.
eEF2K is degraded during silencing of the G2 DNA
damage checkpoint
Because mRNA translation is regulated by mitogens, we analyzed their
effect on the abundance of eEF2K. We serum-starved T98G cells (re-
vertants from T98 glioblastoma cells that acquired the property to ac-
cumulate in G0-G1 after serum deprivation) for 72 hours and then
reactivated them by adding serum. We observed a slight decrease in
the abundance of eEF2K in response to mitogens (fig. S4A). However,
this decrease is not mediated by SCFbTrCP because eEF2K abundance
was not affected when we silenced bTrCP by transfecting T98G cells
with a double-stranded RNA oligonucleotide that efficiently silenced
both bTrCP1 and bTrCP2 (fig. S4A) (33, 38–41).
Because eEF2K is a crucial inhibitor of translation elongation and
because inhibition of protein synthesis is a common response to stress
conditions (8, 10, 23, 42, 43), we analyzed the abundance of eEF2K in
response to hypoxic and genotoxic stress. Hypoxia (and recovery from
it) did not appear to result in detectable changes in the abundance of
eEF2K (fig. S4B). Next, we examined eEF2K abundance in response
to genotoxic stress. U2OS cells were synchronized in the G2 phase of
the cell cycle and then treated with a low dose of doxorubicin to acti-
vate the G2 DNA damage checkpoint. Subsequently, cells were allowed
to recover from the DNA damage checkpoint after extensive washing
in drug-free medium. The abundance of eEF2K steadily decreased dur-
ing checkpoint silencing, paralleling the decrease in the phosphoryl-
ation of Chk2 at Thr68 and that of histone 2AX at Ser139 (Fig. 3A).
A similar pattern of changes in eEF2K abundance was observed in
experiments in which ionizing radiation (Fig. 3B) was used. When
U2OS cells were released into mitosis without DNA damage, eEF2K abun-
dance did not change (fig. S4, C and D). The change in the abundance
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of eEF2K observed in response to DNA damage was not caused by an
indirect cell cycle effect because eEF2K abundance remained steady dur-
ing the cell cycle (fig. S4, C and D).
Treatment of U2OS cells with the proteasome inhibitor MG132
blocked the decrease of eEF2K during checkpoint silencing (Fig.
3C), indicating that the decrease in eEF2K abundance observed during
checkpoint silencing was due to proteasome-dependent degradation.
To test whether bTrCP mediates eEF2K degradation during checkpoint
silencing, we knocked down the expression of bTrCP in U2OS cells by
RNA interference. We then synchronized U2OS cells in G2 and induced
genotoxic stress by doxorubicin treatment (Fig. 3A). bTrCP knockdown
inhibited the degradation of eEF2K during checkpoint silencing (Fig. 3D).
In agreement with this finding, the eEF2K-bTrCP interaction was stimu-
lated in U2OS cells during DNA damage checkpoint silencing (Fig. 3E).
Finally, to analyze the phosphorylation of the eEF2K degron in re-
sponse to genotoxic stress, we generated a phosphospecific antibody that
recognizes eEF2K only when it is phosphorylated on Ser441 and Ser445
(fig. S5A). We found that phosphorylation of the eEF2K degron was
induced by DNA damage in G2 and preceded degradation of eEF2K
(fig. 5SB).
Together, these findings imply that bTrCP targets eEF2K for degrada-
tion upon checkpoint silencing.
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Fig. 1. eEF2K specifically associates with bTrCP1 and bTrCP2 in cells. (A)
HEK293T cells were transfected with the indicated FLAG-tagged F-box
proteins (FBPs) or an empty vector (EV) and treated with MG132 before
lysis. Cell extracts were immunoprecipitated (IP) with anti-FLAG resin and
immunoblotted with the indicated antibodies. (B) HEK293T cells were
transfected with FLAG-tagged eEF2K or an empty vector and treated
as in (A). (C) Endogenous eEF2K and bTrCP1 interact in cells. HEK293T
cells were treated with MG132 before lysis. Lysates were immunoprecipi-
tated with either an affinity-purified polyclonal antibody against eEF2K or
affinity-purified immunoglobulin G (IgG) and then analyzed by immuno-
blotting with antibodies to the indicated proteins. (D) The association of
bTrCP1 (left panels) and bTrCP2 (right panels) with eEF2K requires the
presence of Arg474 in the WD40 repeat of bTrCP1 and Arg447 in the
WD40 repeat of bTrCP2. HEK293T cells were transfected as indicated
and treated as in (A). Data are representative of at least three indepen-
dent experiments.
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AMPK-dependent phosphorylation of eEF2K on Ser398
leads to activation of eEF2K in response to
genotoxic stress
eEF2K controls translation elongation by phosphorylating eEF2 on Thr56
(14, 15, 17–19, 21–23, 44–47), thereby inactivating it. In addition, eEF2K-
mediated phosphorylation of eEF2 on Thr56 inhibits the ribosome-eEF2
complex formation by reducing the affinity of eEF2 for the ribosome.
Our results indicate that phosphorylation of eEF2 on Thr56 increases upon
checkpoint activation and decreases during checkpoint silencing, mir-
roring the phosphorylation profile of bothChk2 on Thr68 (Fig. 3,A andB)
and histone 2AX on Ser139 (Fig. 3A). To confirm that the increased phos-
phorylation of eEF2 on Thr56 in response to DNA damage is mediated by
eEF2K,we silenced the expression of eEF2K inU2OScells byRNA inter-
ference. After transfection, cells were synchronized in G2 and then pulsed
with doxorubicin for 1 hour to induce DNA damage. eEF2K knockdown
blocked the DNA damage–induced phosphorylation of eEF2 on Thr56
(fig. S6A).
Next, we investigated the mechanism by which eEF2K-dependent
phosphorylation of eEF2 is stimulated by genotoxic stress. First, to assess
whether genotoxic stress stimulates the activity of eEF2K, we pulled down
eEF2K from G2 cells treated with doxorubicin and assayed immunopreci-
pitated eEF2K activity against in vitro translated eEF2 (Fig. 4A). The activ-
ity of eEF2K immunoprecipitated from G2 cells treated with doxorubicin
was increased when compared to eEF2K activity in G2 cells.
eEF2K is phosphorylated on Ser398 by AMPK, a phosphorylation
event that leads to eEF2K activation (48). AMPK is activated by the products
of two p53 target genes, Sestrin1 and Sestrin2, in response to genotoxic
stress (49). To test whether genotoxic stress leads to phosphorylation of
eEF2K on Ser398, we used a previously characterized phosphospecific anti-
body that can recognize eEF2K phosphorylated on Ser398 (48). U2OS
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Fig. 2. ThebTrCP-eEF2K interactiondependsonaconservedphosphodegron.
(A) Ser441 and Ser445 in eEF2K are required for the associationwith bTrCP1.
Top: schematic representation of four putative eEF2K phosphodegrons.
Bottom: HEK293T cells were transfected with FLAG-tagged bTrCP1 and
with either an empty vector, HA-tagged eEF2K wild type (WT), or mutants,
treated with MG132, and lysed. Whole-cell extracts were subjected to either
immunoblotting or immunoprecipitationwith anti-FLAG resin and subsequent
immunoblotting. (B) Alignment of the amino acid regions corresponding to
the bTrCP-binding motif (highlighted in yellow) in previously reported bTrCP
substrates and eEF2K orthologs (top). Amino acid sequence of the eEF2K
double mutant is shown (bottom). IkBa, inhibitor of nuclear factor kBa. (C)
Phosphorylation of Ser441 and Ser445 in eEF2K is required for the interaction
withbTrCP1. Invitro translated35S-labeledbTrCP1andFBXW5were incubated
with beads coupled to the indicated eEF2K peptides. Bound proteins were
eluted and subjected to electrophoresis and autoradiography. (D) bTrCP1
ubiquitylates eEF2K in vitro. HEK293T cells were transfected with eEF2K,
Skp1, Cul1, Rbx1, and either FLAG-tagged bTrCP1 or bTrCP1(DF-box).
In vitro ubiquitylation of eEF2K was performed with anti-FLAG immuno-
precipitates, which were immunoblotted with an anti-eEF2K antibody. Data
represent at least three independent experiments.
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cells were synchronized in G2 as described
above and then treated with doxorubicin.
Phosphorylation of eEF2K on Ser398 in-
creased in response to doxorubicin treat-
ment and was associated with increased
phosphorylation of eEF2 on Thr56 (Fig.
4B). To examine the possibility that AMPK
phosphorylates eEF2K on Ser398 in re-
sponse to genotoxic stress, we used the
AMPK inhibitor compound C (49, 50).
Treatment of U2OS cells with compound
C blocked the increase in eEF2K phospho-
rylation on Ser398 and eEF2 phosphoryl-
ation on Thr56 in response to genotoxic stress
(Fig. 4C). To rule out nonspecific effects of
compoundC,we silencedAMPKa byRNA
interference and observed that AMPKa
knockdown inhibited the increase in eEF2
phosphorylation on Thr56 in response to
genotoxic stress (Fig. 4D). Together, these
data indicate that genotoxic stress in G2 cells
stimulates AMPK, which phosphorylates
eEF2K on Ser398, causing its activation. In
turn, activated eEF2K phosphorylates eEF2
on Thr56, blocking its activity.
Moreover, the above results suggest that
translation elongation slows down upon ac-
tivation of the DNA damage checkpoint.
Indeed, G2 cells pulsed with doxorubicin
exhibited increased ribosome transit time
(94 s)—that is, slower rates of elongation—
when compared with untreated G2 cells
(59 s; Fig. 4E).
The observed slowdown in translation
elongation upon activation of the DNA
damage checkpoint was associated with
an eEF2K-dependent decrease in global
protein synthesis as indicated by metabolic
labeling of G2 U2OS cells after genotoxic
stress (fig. S6B).
Autophosphorylation of the
eEF2K degron is required for its
interaction with bTrCP
The above results indicate that in response
to genotoxic stress, eEF2K is first activated
by AMPK-mediated phosphorylation and,
subsequently, during checkpoint silencing,
is targeted for degradation by the ubiquitin
ligase SCFbTrCP. This sequence of events
suggests a coupled activation-destruction
mechanism by which eEF2K is targeted
for destruction when its activity is sustained.
Because eEF2K has autophosphorylation
activity (20, 51), we hypothesized that
eEF2K, once activated, may autophospho-
rylate its degron, thus triggering the binding
of eEF2K to bTrCP. First, to assess whether
eEF2K can phosphorylate itself on Ser441
and Ser445, eEF2K was immunopurified
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Fig. 3. bTrCP-dependent degradation of eEF2K occurs during silencing of the G2 DNA damage
checkpoint. (A) U2OS cells were synchronized in G2, pulsed with doxorubicin (DOX) for 1 hour, washed,
and incubated in fresh medium (indicated as time 0). Cells were harvested at the indicated time points and
analyzed by immunoblotting. (B) U2OS cells were irradiated (10 Gy), collected at the indicated time points,
and analyzed by immunoblotting (UN, untreated). (C) U2OS cells were treated as in (A). MG132 was
added when indicated. (D) U2OS cells were transfected with control or bTrCP siRNAs and treated as
in (A). (E) U2OS cells were transfected with FLAG-tagged bTrCP1(DF-box) or an empty vector and then
treated as in (A). WCE, whole-cell extract. Graphs show eEF2K abundance normalized to a loading con-
trol and relative to the amount present at G2 (A), in untreated (B), or at time 0 (C, D, and E). *P < 0.01
compared with time 0 by one-way analysis of variance (ANOVA). Data represent at least three in-
dependent experiments.
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from U2OS cells, dephosphorylated, and then
subjected to autophosphorylation in vitro.As
a control, we used eEF2K(C314A/C318A), a
kinase-dead eEF2Kmutant that cannot phos-
phorylate either eEF2 or itself (51). eEF2K
phosphorylation on Ser441 and Ser445 was
then analyzed by immunoblotting with the
phosphospecific antibody that recognizes
eEF2K only when it is phosphorylated on
Ser441 and Ser445. The eEF2K degron was au-
tophosphorylated in wild-type eEF2K but not
in the kinase-dead eEF2K mutant (Fig. 5A).
Similar results were obtained with eEF2K
purified from Escherichia coli (fig. S7).
Next, we tested the ability of eEF2K
(C314A/C318A) to bind bTrCP. The kinase-
dead eEF2Kmutant could not interact with
endogenous bTrCP, analogously to the eEF2K
(S441A/S445A) phosphodegron mutant
(Fig. 5B). Accordingly, the eEF2K degron was
phosphorylated in cells in wild-type eEF2K
but not in kinase-dead eEF2K (Fig. 5B).
To exclude the possibility that the in-
ability of eEF2K(C314A/C318A) to inter-
act with bTrCP was indirectly caused by
structural changes in eEF2K, we examined
the binding of wild-type eEF2K in the pres-
ence of NH125, a specific inhibitor of
eEF2K kinase activity (52). Treatment of
U2OS with NH125 abolished both the
phosphorylation of the eEF2K degron and
the bTrCP binding to eEF2K (Fig. 5C) and
resulted in eEF2K stabilization (Fig. 5D).
Altogether, these data strongly suggest
that AMPK-mediated activation of eEF2K
in response to genotoxic stress is required
for eEF2K degradation during checkpoint
silencing. Indeed, inhibition of AMPK by
treatment with compound C prevented
eEF2K degradation during checkpoint silen-
cing (fig. S8). Although necessary, AMPK-
mediated activation of eEF2K is not sufficient
for eEF2K destruction because serum star-
vation, a well-characterized stimulus that
activates AMPK, did not trigger the degra-
dation of eEF2K (fig. S9).
Defective degradation of eEF2K
delays the resumption of
translation elongation during
checkpoint silencing
We then asked whether bTrCP-mediated
degradation of eEF2K is required to resume
protein synthesis upon checkpoint silencing.
U2OS cellswere retrovirally transducedwith
HA-tagged wild-type eEF2K or HA-tagged
eEF2K(S441A/S445A), synchronized in G2
as described above, and subsequently treated
with doxorubicin, released, and then collected
at the indicated times. Compared to cells
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expressingwild-type eEF2K and untransduced cells, cells expressing the
stable eEF2Kmutant that cannot bind bTrCP displayed a slower decrease
in phosphorylation of eEF2 on Thr56 upon silencing of the DNA damage
checkpoint (Fig. 6A). Similar results were obtained in cells recovering
from genotoxic stress induced by ionizing irradiation (Fig. 6B). Moreover,
the abundance of the kinase-dead eEF2K mutant was not decreased during
checkpoint silencing (fig. S10).
Notably, during silencing of checkpoint signaling, cells expressing
eEF2K(S441A/S445A) displayed a longer ribosomal transit time when
compared with cells expressing wild-type eEF2K, indicating a defective
resumption of the normal translation elon-
gation rate when bTrCP-mediated degra-
dation of eEF2K is impaired (Fig. 6C).
Next, we tested whether defective deg-
radation of eEF2K affects global protein
synthesis during checkpoint silencing.
Cells expressing eEF2K(S441A/S445A)
displayed a decreased rate of global protein
synthesis during checkpoint silencing when
compared to control cells, as measured by
metabolic labeling (Fig. 6D). This differ-
ence was not observed in cells that had not
been treated with doxorubicin (fig. S11),
indicating that eEF2K degradation is re-
quired for efficient resumption of global
protein synthesis upon silencing of the DNA
damage checkpoint.
DISCUSSION
eEF2K is a ubiquitous protein kinase that
plays a crucial role in the regulation of
translational elongation by phosphorylating
and inhibiting eEF2, a factor that promotes
ribosomal translocation during the elonga-
tion phase of protein synthesis. In agree-
ment with its key function, eEF2K activity
is tightly controlled by different upstream
protein kinases, which either block or stim-
ulate its function in response to different
stimuli (24). In addition to this level of reg-
ulation, eEF2K abundance is controlled
by the ubiquitin-proteasome system (53);
however, the biological importance of the
ubiquitylation and degradation of eEF2K
and the identity of the E3 ubiquitin ligase
involved are unknown. Here, we show that
after the activation of the DNA damage
checkpoint, AMPK mediates the activation
of eEF2K, which in turn phosphorylates
eEF2, leading to a decrease in translation
elongation rates. Subsequently, eEF2K au-
tophosphorylation generates a phospho-
degron for the recruitment of the ubiquitin
ligase SCFbTrCP. This event triggers the
ubiquitylation of eEF2K and its proteasome-
mediated degradation, which releases the
inhibitory effect on eEF2 and translation
elongation (Fig. 7). The coupled activation-
destruction of eEF2K represents a mech-
anism that generates a pulse of kinase
activity to dynamically tune the rate of elon-
gation in response to genotoxic stress. This
mechanism, by which eEF2K is targeted for
degradation when its activity is sustained,
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would imply that any condition that induces the activity of eEF2K would
inevitably trigger eEF2K destruction. However, bTrCP-mediated deg-
radation of eEF2K, which occurs specifically in response to DNA dam-
age, suggests that additional regulatory mechanisms must exist to prevent
degradation of eEF2K after other activating conditions. Possible protective
roles of protein phosphatases (that counteract eEF2K autophosphoryl-
ation), deubiquitinating enzymes (that cleave
ubiquitin chains conjugated on eEF2K
through SCFbTrCP), and chaperone pro-
teins (that shield eEF2K from ubiquitin
conjugation) in response to stress condi-
tions different from DNA damage need to
be investigated. It has been observed that
eEF2K is chaperoned by Hsp90 and that
cellular abundance of eEF2K is controlled
by a balance between association with
Hsp90 and degradation by the ubiquitin-
proteasome system (53).
We cannot rule out that only one of the
two serine residues within the eEF2K degron
(Ser441 and Ser445) is the autophosphoryl-
ation site. Indeed, liquid chromatography–
MS/MS (LC-MS/MS) analysis of the
eEF2K degron after in vitro autophospho-
rylation revealed that Ser445 is the predom-
inant phosphorylated site, implying that
another kinase targets Ser441. According
to this model, the specific degradation of
eEF2K in response to DNA damage would
be triggered by the cooperative actions of
two kinases. The combination of eEF2K
autophosphorylation (which targets Ser445)
and a yet to be identified kinase (that tar-
gets Ser441) would be needed to generate
the eEF2K phosphodegron specifically in
response to DNA damage.
Regulation of translation elongation in
response to DNA damage might have sev-
eral advantages over controlling translation
initiation. Indeed, elongation inhibition
during checkpoint activation avoids the dis-
assembly of polysomes, which, by stalling
ribosomes on the mRNAs, might allow for
mRNA protection from degradation or
sequestration into stress granules, for ex-
ample. This mechanism will also ensure
that translation can rapidly resume when
the checkpoint is turned off.
General inhibition of translation coupled
with stimulation of translation of specific
mRNA pools has been demonstrated at
the levels of both initiation and elongation.
For instance, DNA-PKcs (DNA-dependent
protein kinase catalytic subunit)–mediated
translation reprogramming in response to
ultraviolet radiation allows selective syn-
thesis of DNA damage response proteins
and is based on upstream open reading
frames in the 5′ untranslated region of these
mRNAs (54). Other studies have shown
that eEF2K-dependent phosphorylation
of eEF2 acts to slow down the elongation
step of translation and inhibits general
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protein synthesis but simultaneously increases the translation of themRNAs
encoding Arc (activity-regulated cytoskeleton-associated protein; also
known as Arg3.1), a neuronal immediate-early gene involved in both
synapse plasticity and long-term potentiation (55). Microarray analysis of
polysome- andmonosome-associatedmRNApoolswill be required to iden-
tify mRNAs that are translated only during the DNA damage checkpoint.
SCFbTrCP is implicated in the degradation of several substrates during
the recovery from DNA damage and replication stress checkpoints. In-
deed, bTrCP is required to reactivate the cyclin-dependent kinase Cdk1
by targeting the Cdk1 inhibitors Claspin and Wee1 for proteasome-
dependent degradation (35, 41, 56–60) and turn off the DNA repair ma-
chinery by causing the destruction of the Fanconi anemia protein FANCM
(61). Our findings show that bTrCP is also needed during checkpoint si-
lencing to resume protein synthesis by triggering proteolysis of eEF2K,
suggesting that the ubiquitin ligase SCFbTrCP coordinates different pro-
cesses (such as cell cycle progression, DNA repair, and protein synthesis)
that are critical for checkpoint termination.
MATERIALS AND METHODS
Cell culture, synchronization, and drug treatment
HEK293T, 293GP2, and U2OS cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM; Invitrogen) containing 10% fetal calf
serum. HCT116, SW480, and MCF7 cells were maintained in DMEM/
Nutrient Mixture F-12 (DMEM/F-12) containing 10% fetal calf serum.
Synchronizations and flow analysis were performed as described (38).
MG132 (10 mM) was added when indicated.
Biochemical methods
Extract preparation, immunoprecipitation, and immunoblotting were per-
formed as previously described (33, 40).
Purification of bTrCP2 interactors
HEK293T cells were transfected with pcDNA3-FLAG-HA-bTrCP2 and
treated with 10 mM MG132 for 5 hours. Cells were harvested and sub-
sequently lysed in lysis buffer [50 mM tris-HCl (pH 7.5), 150 mMNaCl,
1 mM EDTA, and 0.5% NP-40 plus protease and phosphatase inhibi-
tors]. bTrCP2 was immunopurified with anti-FLAG agarose resin (Sigma).
Beads were washed, and proteins were eluted by competition with FLAG
peptide (Sigma). The eluate was then subjected to a second immuno-
purification with anti-HA resin (12CA5 monoclonal antibody cross-linked
to protein G–Sepharose; Invitrogen) before elution in Laemmli sample
buffer. The final eluate was separated by SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE), and proteinswerevisualized byCoomassie colloidal
blue. Bands were sliced out from the gels and subjected to in-gel digestion.
Gel pieces were then reduced, alkylated, and digested according to a pub-
lished protocol (62). For mass spectrometric analysis, peptides recovered
from in-gel digestion were separated with a C18 column and introduced
by nano-electrospray into an LTQOrbitrap XLmass spectrometer (Thermo
Fisher). Peak lists were generated from theMS/MS spectra withMaxQuant
(63), and then searched against the International Protein Index human
database with Mascot search engine (Matrix Science). Carbamino-
methylation (+57 daltons) was set as fixed modification and protein N-
terminal acetylation and methionine oxidation as variable modifications.
Peptide tolerance was set to 7 parts per million (ppm) and fragment ion tol-
erance was set to 0.5 daltons, allowing two missed cleavages with trypsin
enzyme.
Antibodies
Mouse monoclonal antibodies were from Invitrogen (Cul1), Sigma
(FLAG, eEF2K), Santa Cruz Biotechnology (actin), BD (b-catenin,
p27), and Covance (HA). Rabbit polyclonal antibodies were from Bethyl
(PDCD4), Cell Signaling [bTrCP1, eEF2K, eEF2, phospho-eEF2(Thr56),
phospho-Chk2(Thr68)], Millipore [phospho-histone H3(Ser10), phospho-
histone H2AX(Ser139)], Sigma (FLAG, USP8), Novus Biologicals
(HIF1a), and Santa Cruz (cyclin A, Cdc20, Skp1, and HA).
Plasmids
eEF2K mutants were generated with the QuikChange Site-Directed Mu-
tagenesis kit (Stratagene). For retrovirus production, both wild-type
eEF2K and eEF2K mutants were subcloned into the retroviral vector
pBABEpuro. All complementary DNAs (cDNAs) were sequenced.
Transient transfections and retrovirus-mediated
gene transfer
HEK293T cells were transfected with the calcium phosphate method as
described (33, 40). Retrovirus-mediated gene transfer was performed as
previously described (33, 40).
Gene silencing by small interfering RNA
The sequence and validation of the oligonucleotides corresponding to
bTrCP1 and bTrCP2 were previously published (33, 40, 41, 64). Both
eEF2K and AMPKa SMARTpool small interfering RNA (siRNA) oligo-
nucleotides were from Dharmacon. Cells were transfected with the oligos
twice (24 and48hours after plating) by theuse ofOligofectamine (Invitrogen)
according to the manufacturer’s recommendations. Forty-eight hours after
the last transfection, lysates were prepared and analyzed by SDS-PAGE and
immunoblotting.
In vitro ubiquitylation assay
eEF2K ubiquitylation was performed in a volume of 10 ml containing
SCFbTrCP-eEF2K immunocomplexes, 50 mM tris (pH 7.6), 5 mM
MgCl2, 0.6 mM dithiothreitol (DTT), 2 mM adenosine triphosphate
(ATP), 2 ml of in vitro translated unlabeled bTrCP1, E1 (1.5 ng/ml; Boston
Biochem), Ubc3 (10 ng/ml), ubiquitin (2.5 mg/ml; Sigma), and 1 mM
AMPK
eEF2K
eEF2
Translation elongation
+ SCFβTrCP
Checkpoint initiation Checkpoint silencing
AMPK
eEF2K
eEF2
Translation elongation
Fig. 7. Model of eEF2K regulation in response to genotoxic stress. Black
lines represent activated proteins, and gray indicates inactive or degraded
proteins. See text for details.
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ubiquitin aldehyde. The reactions were incubated at 30°C for the indicated
times and analyzed by immunoblotting. In the assay shown in fig. S3,
35S-labeled in vitro translated eEF2K [wild type or eEF2K(S441A/S445A)]
was used instead of immunoprecipitated eEF2K. The reactions were an-
alyzed by SDS-PAGE and autoradiography.
Phosphorylation analysis of the eEF2K degron in cells
FLAG-eEF2K was coexpressed with the Cul1 dominant-negative deletion
mutant CUL1-N252, and immunopurified. FLAG immunocomplexes
were eluted with 8 M urea. Samples were then reduced with 10 mM
DTT for 30 min at 60°C followed by addition of iodoacetamide to
20 mM followed by 30-min incubation in the dark at room temperature.
The first digestion was performed with Lys-C for 4 hours at 37°C. Sub-
sequently, the digest was diluted fivefold with 50 mM ammonium bi-
carbonate to a final urea concentration of less than 2 M, and a second
digestion with trypsin was performed overnight at 37°C. Finally, the diges-
tion was quenched by addition of formic acid to a final concentration of
0.1% (vol/vol). The resulting solution was desalted with 200-mg Sep-Pak
C18 cartridges (Waters Corporation), lyophilized, and stored at −20°C.
Ti-IMAC microcolumns were prepared as previously described (65).
Trypsinized peptides were loaded onto preconditioned microcolumns,
which were later sequentially washed with 60 ml of loading buffer
followed by 60 ml of 50% acetonitrile (ACN)/0.5% trifluoroacetic acid
(TFA) containing 200 mM NaCl and 60 ml of 50% ACN/0.1% TFA.
The bound peptides were eluted by 20 ml of 5% ammonia into 20 ml of
10% formic acid and then stored at −20°C before LC-MS/MS analysis.
MS spectra assignment was performed with MaxQuant version 1.1.1.25.
In vitro kinase assay
eEF2K kinase activity was assayed as described (48).
Ribosome transit time measurements
The method for ribosome transit time measurements is adapted from
(45, 66). In brief, cells were incubated in methionine-free medium for 30min
before addition of labeling medium containing L-[35S]methionine (10 mCi/ml)
(NEG709A, PerkinElmer). Samples were harvested in phosphate-buffered
saline (PBS) containing cycloheximide (100 mg/ml) at 2, 4, 6, 8, 10, and
12 min after labeling and pelleted. Cell lysis and pelleting of polysomes
were executed as described (66). Polysomes were pelleted at 55,000g for
20 min at 4°C in a Beckman Sw55Ti rotor.
Fifty microliters of the total protein fraction (postmitochondrial super-
natant) and completed protein fraction (postribosomal supernatant) was
loaded on 3MM paper and precipitated by consecutive incubations in cold
10% trichloroacetic acid (TCA) and boiling 10% TCA (2.5 min per step)
and briefly washed in acetone and ethanol. Filters were air-dried, and in-
corporation of [35S]methionine was measured by liquid scintillation
counting (three measurements per sample).
To calculate ribosome transit times, we measured the lag between the
linear incorporation of labeled methionine in total protein (TP) and the
linear incorporation in complete protein (CP), which represents the time
it takes for all nascent peptides to be labeled (67). This lag is seen in the
graph as the difference in x intercepts of the two extrapolated lines and
represents the half-transit time (half because the average length of poly-
peptides on a polyribosome is always half of the full length of completed
peptides). To obtain the ribosome transit time, we doubled the difference
in intercepts.
Metabolic labeling
U2OS cells were cultured in methionine-free medium for 60 min and then
incubated in 50 mM Click-iT HPG (L-homopropargylglycine) for 90 min.
Cells were fixed in 70% ethanol, stained with Alexa Fluor 488 azide, and
analyzed by fluorescence-activated cell sorting.
Statistical analysis
All data shown are from one representative experiment of at least three
performed. Statistical tests used are specified in the legends of relevant
figures.
SUPPLEMENTARY MATERIALS
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Fig. S1. eEF2K interacts with bTrCP1 and bTrCP2.
Fig. S2. Phosphorylation of the eEF2K degron in cells.
Fig. S3. bTrCP-mediated ubiquitylation of eEF2K depends on an intact phosphodegron.
Fig. S4. eEF2K abundance in response to mitogens and during the cell cycle.
Fig. S5. The eEF2K degron is phosphorylated in response to genotoxic stress.
Fig. S6. DNA damage–dependent phosphorylation of eEF2 on Thr56 and decreased protein
synthesis are mediated by eEF2K.
Fig. S7. In vitro autophosphorylation of the eEF2K degron.
Fig. S8. AMPK inhibition prevents eEF2K degradation during checkpoint silencing.
Fig. S9. Serum starvation, a stimulus that activates AMPK, does not lead to eEF2K
degradation.
Fig. S10. The kinase-dead eEF2K mutant is not degraded during checkpoint silencing.
Fig. S11. Expression of the eEF2K(S441A/S445A) mutant in exponentially growing U2OS
cells does not lead to decreased protein synthesis.
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